Biomarkers used to detect and monitor neurological autoimmune diseases

Patent metadata

Field	Value
Publication number	US-9304123-B2
Application number	US-201313962571-A
Country	US
Kind code	B2
Filing date	Aug 8, 2013
Priority date	Aug 8, 2012
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

Biomarkers of neurological autoimmune diseases are described, and methods of using such biomarkers also are described.

First claim

What is claimed is:

1. A method of monitoring the progression of EAE in a rodent comprising:
collecting a urine sample from a rodent having EAE; and
determining the levels of one or more biomarkers in the rodent's urine, wherein the one or more biomarkers compromise 3-ureidopropionic acid;
wherein an increase in the level of the one or more biomarkers in the rodent's urine is indicative of the progression of EAE in the rodent.

2. The method of claim 1 , wherein the one or more biomarkers further comprise guanidinoacetate.

3. The method of claim 1 , wherein the one or more biomarkers further comprise indoxyl sulfate.

4. The method of claim 1 , wherein the one or more biomarkers further comprise guanidinoacetate and indoxyl sulfate.

5. The method of claim 1 , wherein the levels of the one or more biomarkers are determined using an immunoassay, chromatography, spectroscopy or NMR.

6. The method of claim 1 , wherein the levels of the one or more biomarkers in the rodent's urine are compared to the levels of the one or more biomarkers in a control rodent that does not suffer from EAE.

7. The method of claim 1 , wherein the levels of the one or more biomarkers in the rodent's urine are compared to a standardized control.

8. A method of determining whether a compound is effective for ameliorating the symptoms of EAE in a rodent, comprising:
collecting a first urine sample from a rodent having EAE;
determining the levels of one or more biomarkers in the first urine sample, wherein the one or more biomarkers comprise 3-ureidopropionic acid;
administering a compound to the rodent having EAE;
collecting a second urine sample from the rodent having EAE; and
determining the levels of the one or more of the biomarkers in the second urine sample,
wherein a decrease in the level of one or more biomarkers in the second urine sample relative to the first urine sample is indicative of a compound that is effective for ameliorating the symptoms of EAE in a rodent.

9. The method of claim 8 , wherein the one or more biomarkers further comprise guanidinoacetate.

10. The method of claim 8 , wherein the one or more biomarkers further comprise indoxyl sulfate.

11. The method of claim 8 , wherein the one or more biomarkers further comprise guanidinoacetate and indoxyl sulfate.

12. The method of claim 8 , wherein the levels of the one or more biomarkers are determined using an immunoassay, chromatography, spectroscopy or NMR.

Assignees

• Nutech Ventures

Inventors

• Powers Robert
• Reddy Jay
• Gebregiworgis Teklab
• Massilamany Chandirasegaran
• Gangaplara Arunakumar
• Illes Zsolt

Classifications

• G01N33/5308

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title

• G01N33/493 Primary

  urine · CPC title

• G01N2500/10

  involving cells · CPC title

• G01N2800/285

  Demyelinating diseases; Multipel sclerosis · CPC title

• G01N33/564 Primary

  for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9} · CPC title